Drug intelligence / Profile preview

virginiamycin S1

Development stage
Unknown
Lead developer
Pfizer
Modality
Peptides, Small Molecules
Administration
Oral
01

Overview

Virginiamycin S1 is a cyclodepsipeptide antibiotic and one of the two major components of the streptogramin antibiotic complex known as virginiamycin, which is produced by various Streptomyces species including Streptomyces virginiae. It belongs to the streptogramin B group and acts as a macrolide antibiotic. Virginiamycin S1 inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, thereby blocking aminoacyl-tRNA binding and peptide bond formation. This action disrupts protein synthesis in gram-positive bacteria, leading to bacteriostatic or bactericidal effects depending on context. Virginiamycin (as a mixture of M1 and S1) is used primarily in veterinary medicine for treating infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. It also finds use in industrial fermentation processes such as bioethanol production to prevent microbial contamination[2][3][4][5][8].

Other names
staphylomycin Svirginiamycin factor Svirginiamycin S
02

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on virginiamycin S1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on virginiamycin S1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call